De-Risk Biologics' Expression And Manufacturing Through Early In Silico And In Vitro Assessments

An increasingly competitive industry landscape is compounding the challenges for drug developers already facing growing pressure to drive down the overall cost and timeline from discovery to patients. However, adopting strategies to identify the most promising candidates as early as possible helps facilitate predictions about potential manufacturability, expression, and process development challenges that threaten a product’s path to market.

Rebecca Michael, Ph.D., Head of Cell and Molecular Biology, in Lonza Early Development Services recently presented a webinar about how in silico and in vitro design and optimization tools can help drug developers not only assess these risks but also mitigate them. She also discussed how to optimize early expression and material supply to secure optimal developability of a candidate. These activities are designed to ensure that early process development efforts are focused on key developability challenges in order to minimize scale-up risk. The webinar included case studies to illustrate how these activities can maximize the chance of success in the development journey.

The following Q&A session was held after this webinar, where Lyon and Adam addressed attendee questions about the details of the methods and case studies.